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PURPOSE. The purpose of this study was to characterize fundus autofluorescence lifetimes of
retinal drusen in patients with AMD.
METHODS. Patients with AMD and retinal drusen and healthy controls of similar age were
examined. A fluorescence lifetime imaging ophthalmoscope was used. Retinal autofluores-
cence was excited using a 473-nm pulsed laser, and fundus autofluorescence lifetimes of the
central retina (308) were measured in two distinct spectral channels (short: 498 to 560 nm
[SSC]; long: 560 to 720 nm [LSC]). Mean retinal autofluorescence lifetimes, corresponding
fundus autofluorescence intensity images, spectral domain optical coherence tomography,
color fundus images, and clinical data were investigated. Patients were analyzed in two
distinct groups (soft drusen and reticular pseudodrusen) and compared with control subjects.
RESULTS. Sixty-four eyes of 64 patients with AMD and retinal drusen (age: mean 6 SD, 78 6
8.5 years; range, 59 to 94 years) were investigated and compared with a control group of 20
age-matched healthy subjects. Mean retinal autofluorescence lifetimes in patients with AMD
was significantly prolonged compared with the healthy control eyes (mean 6 SEM: SSC, 486
6 18 vs. 332 6 11 ps, P < 0.0001; LSC: 493 6 9 vs. 382 6 17 ps, P < 0.0001). Areas of
drusen featured a wide range of fluorescence lifetime values. Long lifetimes were identified in
areas of atrophy and in areas of intraretinal hyperreflective deposits. Short lifetimes
corresponded to deposits within the photoreceptor outer segment band.
CONCLUSIONS. Mean retinal autofluorescence lifetimes in AMD patients are significantly
prolonged. Intraretinal deposits cause prolonged lifetimes, whereas deposits in the area of the
outer photoreceptor segments lead to short fluorescence lifetimes.
Keywords: fluorescence lifetimes, fundus autofluorescence, retinal imaging, FLIO, age-related
macular degeneration, AMD, deposits, drusen
AMD is caused by age-related metabolic disorders in theretina, which leads to thickening of the Bruch membrane
with calcifications, basal laminar deposits, and appearance of
drusen. The predominant symptom is progressive central vision
loss. The prevalence of advanced AMD is estimated to increase
from 2.2% in 65-year-old patients to more than 21% in patients
older than 90 years.1 Various risk factors have been identified,
including age, sex, arterial hypertension, arteriosclerosis,
elevated serum lipids, smoking, alcohol abuse, exposure to
UV light, and various genetic factors.2–6
The hallmark of early AMD is the presence of retinal drusen,
which can be classified into soft drusen of various sizes (small,
medium, large), hard drusen, cuticular drusen, crystalline
drusen, and reticular pseudodrusen.4,7 In the biomicroscopic
fundus examination, drusen are seen as discrete, yellow-white
punctuate elevations. Retinal drusen are focal deposits of
extracellular debris located between the basal lamina of the
RPE and the inner collagenous layer of the Bruch membrane
and are mainly concentrated within the posterior pole. The
largest single component of drusen is lipid. Other elements are
carbohydrates, zinc, and nearly 150 proteins, including
vitronectin and apolipoproteins E and B.8 Most of the
components are photoreceptor- and mitochondria-derived
proteins and thus involved in the lipofuscin metabolism.9 Hard
drusen have a diameter of less than 30 to 63 lm and their
borders are very confined. Soft drusen typically have a diameter
of 63 lm to more than 125 lm, and their outer borders may be
confluent. In fluorescein angiography (FA), soft drusen are
usually minimally hyperfluorescent in late stages. Histopatho-
logic investigations showed that soft drusen are mounds basal
to the RPE basement membrane containing lipoprotein-derived
debris and thus can disturb the architecture of the RPE.
Reticular pseudodrusen, on the other hand, are located in the
subretinal space rather than being sub-RPE. They are mainly
distributed perifoveally, and their size ranges from 25 lm to
more than 125 lm. According to postmortem studies, reticular
pseudodrusen share superficial ultrastructural and compositional
similarities with soft drusen.4,10 On optical coherence tomogra-
phy (OCT) scans, reticular pseudodrusen are visible as granular
hyperreflective deposits between the RPE and the inner segment
ellipsoid lines.4,8 They can be large enough to break through the
ellipsoid line and disturb or shorten the overlying photorecep-
tors and form conical accumulations that can breach the external
limiting membrane. Reticular pseudodrusen are especially visible
in near infrared reflectance imaging and may appear hypofluor-
escent in fluorescein angiography.4
Small drusen (<63 lm) can be a sign of normal retinal aging
changes and are not associated with increased risk of late AMD
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development. However, medium drusen (63 to 125 lm) should
be considered early AMD. Intermediate AMD is characterized
by large drusen (>125 lm) and/or pigmentary abnormalities
associated with at least medium drusen. Neovascular AMD
and/or geographic atrophy are signs of late AMD. Five-year
risks of progressing to late AMD are estimated to increase
approximately 100-fold depending on the actual stage of AMD,
ranging from a 0.5% 5-year risk for normal aging changes to a
50% risk for the highest-intermediate AMD risk group.2,11,12
Fluorescence lifetime imaging ophthalmoscopy (FLIO) can
identify early retinal changes in degenerative retinal diseases and
has been shown to provide not only information about the
integrity of the RPE but of the photoreceptors as well.13–22 FLIO
measures the lifetime time span of naturally occurring retinal
fluorophores on excitation with a blue laser light impulse.
Fluorescence lifetimes are specific for each molecule. They are
known to be independent of the fluorescence intensity and are
influenced by the local metabolic environment.23
First studies measuring fluorescence lifetimes in AMD have
shown prolonged lifetimes compared to healthy subjects.24,25
Detailed analysis of drusen as the hallmark of early and
intermediate AMD, and identification of early metabolic and
structural changes in AMD could help to identify patients at
risk and may be helpful for predicting disease development and
progression.
METHODS
All participants were recruited from the outpatient clinic of the
department of ophthalmology at the University Hospital in
Bern, Switzerland. The study protocol was approved by the
local ethics committee and is in accordance with the
Declaration of Helsinki and the International Ethical Guidelines
for Biomedical Research involving Human Subjects (Council for
International Organizations of Medical Sciences [CIOMS]). The
study is registered at ClinicalTrials.gov (NCT01981148) with
the title ‘‘Measurement of Retinal Autofluorescence with a
Fluorescence Lifetime Imaging Ophthalmoscope.’’ Informed
written consent was obtained from all participants before
study entry.
Subjects and Procedures
A standardized sequence of investigations was performed for
every patient, which included measurement of best-corrected
visual acuity (Early Treatment Diabetic Retinopathy Study
[ETDRS] letters)26 and measurement of intraocular pressure
using air tonometry as a noncontact system to avoid corneal
staining with fluorescein. After maximal pupil dilation with
tropicamid 0.5% and phenylephrine hydrochloride 2.5%, a
general ophthalmic examination by a retinal specialist was
performed. Eyes with ocular pathologies besides AMD such as
media opacities and other retinal pathologies were excluded to
avoid potential imaging artifacts. Multimodal imaging of the
central 308 retinal field was performed including optical
coherence tomography (OCT) and fundus autofluorescence
(FAF) measurement (Heidelberg Spectralis HRAþOCT; Heidel-
berg Engineering, Heidelberg, Germany), fundus color imaging
(Zeiss FF 450plus; Carl Zeiss Meditec, Jena, Germany), and
fluorescence lifetime imaging ophthalmoscopy (Heidelberg
Engineering).
Stages of AMD were classified as follows: early AMD with
small to medium drusen, intermediate stage with large (>125
lm) more confluent drusen and/or pigmentary abnormalities,
and late AMD with geographic atrophy or exudative AMD with
intraretinal fluid as sign of retinal neovascularisation.11 The
existing drusen were divided into soft drusen and reticular
pseudodrusen according to their appearance in OCT and the
corresponding infrared image.4 Data were further analyzed
considering the lens status (phakic or pseudophakic).
Fluorescence Lifetime Imaging Ophthalmoscope
and Image Analysis
Fluorescence lifetime data were acquired using a fluorescence
lifetime imaging ophthalmoscope based on a Heidelberg retina
angiograph (HRA) Spectralis system (Heidelberg Engineering).
The FLIO system and its technical background are described in
previous publications including detailed laser safety calcula-
tions.13,14
Retinal autofluorescence was excited using a 473-nm
pulsed laser raster-scanning the central fundus (308) with a
repetition rate of 80 MHz. The laser exposure is well below the
limits set by the International Electrotechnical Commission.27
Emitted photons were detected by highly sensitive hybrid
photon-counting detectors (HPM-100-40; Becker&Hickl, Ber-
lin, Germany) and registered by time-correlated single-photon
counting (TCSPC) modules (SPC-150; Becker&Hickl). Photons
were separately detected in two channels according to their
wavelength: in a short spectral channel (wavelengths 498 to
560 nm, SSC) and in a long spectral channel (560 to 720 nm,
LSC). A minimum of 1000 photons per pixel was recorded
within the macular center in both channels. In parallel, eye
movements were tracked by an inbuilt infrared reflectance
camera to ensure correct allocation of detected photons within
the 256 3 256-pixel frame.
Recorded fluorescence lifetime data were analyzed using
SPCImage 5.4 software (Becker&Hickl). A binning factor of one
was applied, averaging the photons of an individual pixel point
with the directly adjacent pixels to increase the numbers of
photons per pixel. A fluorescence decay histogram was
generated for every single data point in both spectral channels
using a bi-exponential decay function.
The resulting individual lifetime components within the SSC
and the LSC were a short (T1) and a long (T2) decay time with
their corresponding relative amplitudes (¼relative intensity) a1
and a2, whereby T1 << T2 and a1 >> a2.
Of these four components T1, T2, a1, and a2, the mean
fluorescence lifetime tau mean (Tm) can be calculated. It
represents the amplitude weighted mean fluorescence decay
time per pixel and wavelength channel.
Tm ¼ a1  T1 þ a2  T2
a1 þ a2 ð1Þ
FLIO data was averaged and analyzed using the custom made
FLIO reader (ARTORG Center for Biomedical Engineering
Research, University of Bern, Bern, Switzerland). A standard
ETDRS grid (Circle diameters central area [C] 1 mm, inner ring
[IR] 3 mm, outer ring [OR] 6 mm) was used for analysis of
individual retinal areas.13 For analysis of specific regions of
interest (ROI), a small circle with 0.2 mm diameter was used.
The primary outcome was the mean fluorescence lifetime
Tm. Further values of interest were the short (T1) and the long
(T2) lifetime components with the corresponding amplitudes
a1 and a2 as the individual components of Tm.
Statistical Analysis
For statistical analysis, only data of one eye per patient was
used. If applicable, the eye with the better image quality was
chosen; otherwise, one eye was selected randomly. Values are
shown as mean 6 SEM. All statistical analysis was done using
Graph Pad Prism version 6 (GraphPad Software, Inc., La Jolla,
CA, USA). Data groups were compared using a two-tailed t-test
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for parametric data with a confidence interval of 95%. P < 0.05
was considered statistically significant.
RESULTS
Sixty-four patients with retinal drusen were included in this
study; 62.5% (n¼ 40) were female. The age ranged from 59 to
94 years, with a mean of 78 years (68.5 SD). Two eyes (3%)
had early AMD, 28 eyes (44%) had intermediate AMD, 13 eyes
(20%) had dry AMD, and 21 eyes (33%) had exudative AMD;
46.9% (N¼ 30) of the eyes showed predominantly soft drusen,
whereas 53.1% (n ¼ 34) exhibited mainly reticular pseudo-
drusen. Thirty-nine percent of the eyes (n ¼ 25) were
pseudophakic. The mean best-corrected visual acuity was 71
6 1.9 SEM ETDRS letters (range, 23–93). A control group of
20 eyes of 20 age-matched participants was used (range, 59 to
87 years; mean, 75 years; SD, 8.5; P ¼ 0.13). An overview of
patient characteristics is provided in the Table.
Fluorescence Lifetimes in Patients With AMD and
Retinal Drusen
Mean retinal autofluorescence lifetimes in patients with AMD
and reticular pseudodrusen and/or soft drusen were significant-
ly prolonged compared with the healthy control eyes (Fig. 1). In
phakic eyes, mean lifetime values 6 SEM of the outer ETDRS
ring were 613 6 29 ps compared with 346 6 13 ps in healthy
controls in the SSC, and 545 61 7 ps compared with 370 6 13
ps in the LSC (both P < 0.0001). In pseudophakic eyes, mean
lifetime values were 404 6 8 ps compared with 325 6 15 ps in
healthy controls in the SSC (P ¼ 0.0004) and 475 6 9 ps
compared with 419 6 22 ps in the LSC (P¼ 0.0145).
The ROI of drusen and the surrounding retina within the
area of the outer ETDRS ring featured a broader range of
fluorescence lifetime values. The mean fluorescence lifetimes
of reticular pseudodrusen ranged from 325 to 1093 ps with a
mean of 554 ps in the SSC and from 349 to 726 ps with a mean
of 536 ps in the LSC. The mean fluorescence lifetimes of soft
drusen ranged from 311 to 813 ps with a mean of 468 ps in the
SSC and from 321 to 650 ps with a mean of 476 ps in the LSC.
The mean autofluorescence lifetime within specific ROIs are
summarized in Figure 2.
The detailed analysis of individual lifetime components of
Tm (T1, T2, a1, and a2; see Methods, Equation 1) did not
contribute to a better identification of soft drusen or reticular
pseudodrusen.
Correlation of Fluorescence Lifetimes Data With
Findings in OCT
Drusen were colocalized using corresponding OCT, IR, FAF,
and FLIO images. Soft drusen with subretinal accumulation of
hyperreflective material identified in OCT showed distinctively
shortened lifetimes compared with the surrounding retina (Fig.
3A). Soft drusen with hyporeflective sub-RPE material did not
show fluorescence lifetime differing from the surrounding
retina (Figs. 2A, 3A). However, intraretinal hyperreflective
deposits led to marked prolongation of lifetimes (Fig. 3B) even
in the presence of surrounding short lifetime drusen. Reticular
pseudodrusen generally displayed slightly longer lifetimes
compared with soft drusen (Fig. 2C).
Distribution Histogram of Fluorescence Lifetime
Components
Figure 4 shows a representative example of a two-dimensional
(2D) distribution histogram in a patient with short and long
mean lifetime deposits. The short lifetime component T1 (see
Equation 1) was in the range of 150 to 350 ps and the long
decay component T2 between 1500 and 2500 ps. Using 2D
distribution clouds, areas of prolonged or shortened mean
fluorescence lifetimes were visible. Compared with the main
retina, deposits with short mean fluorescence lifetime values
featured significantly shorter T1, whereas drusen with long
mean fluorescence lifetimes mainly showed longer lifetime
components T2. (Figs. 4A, 4B)
DISCUSSION
Autofluorescence lifetime imaging in patients with AMD
revealed a generalized prolongation of retinal lifetimes within
the ETDRS grid compared with age-matched healthy controls
independent of the presence or absence and the type of drusen
(soft drusen or reticular pseudodrusen). These data are in
keeping with previous studies of FLIO in AMD24 and ex vivo
fluorescence lifetime data of human donor retinal tissue
containing extramacular drusen.28 Our data shows that sub-
and intraretinal deposits feature characteristic lifetime patterns
that may yield information about their composition and
duration of existence. It should be kept in mind that the
human lens itself has a long fluorescence lifetime and may
therefore influence fluorescence lifetime dynamics of the
retina. This is evident from our data, where the differences of
mean lifetime between AMD patients and healthy controls
were 257 ps in the short wavelength channel for phakic eyes
and only 79 ps for pseudophakic eyes. This infers that
fluorescence lifetimes are influenced by the fluorescence of
the crystalline lens, especially in older patients. However, the
trend of lifetime changes between AMD patients and healthy
subjects in our study was comparable for phakic and for
pseudophakic eyes. For quantitative measurements, it may be
useful to incorporate the influence of the human lens for
quantification of retinal lifetimes.
The general prolongation of retinal fluorescence lifetime is
not surprising in synopsis with results from fluorescence
lifetime measurements in other retinal pathologies and
progressive age,16,18,21 and can be explained by accumulation
of lipofuscin, as well as progressive remodeling of the retina
with possibly increasing content of connective tissue compo-
nents such as collagen, which have been shown to exhibit long
fluorescence lifetimes.29 Elevated lipofuscin contained in the
RPE may precede or coexist with the earliest stages of
pathology in AMD.30 However, in the late stages of AMD,
RPE lipofuscin is decreased.
TABLE. Overview of Patient Characteristics
No., % Age, y (Mean 6 SD) Female, y Male, y BCVA (Mean 6 SD) Phakic, % Psudophakic, %
All patients 64 77.9 6 8.5 40 24 71.3 6 14.9 39 (61%) 25 (39%)
Soft drusen 30 (47%) 73.2 6 8.6 19 11 75.7 6 12.9 20 10
Reticular drusen 34 (53%) 82.3 6 6.0 21 13 67.4 6 15.7 19 15
Healthy subjects 20 74.5 6 8.5 3 17 79.9 6 9.4 15 5
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Soft drusen, irrespective of the size and height of
hyporeflective subretinal deposits in OCT, did not stand out
from the surrounding retina in fluorescence lifetime measure-
ments. In autofluorescence intensity imaging, drusen have an
extremely variable appearance depending on size and integrity
of the overlying RPE and ellipsoid zone. Whereas large and
confluent soft drusen may result in hyperfluorescent autofluo-
rescence changes, smaller drusen are often iso-autofluorescent
and remain undetected in fundus autofluorescence imaging.
In FLIO, soft drusen did not contrast to the surrounding
retinal tissue, and this may be explained either by the absence
of fluorescing material within soft drusen, or the absence of
autofluorescence for the given excitation wavelength of 473
nm. However, in the presence of intra- or subretinal hyper-
reflective deposits, as identified in OCT, fluorescence lifetime
changes colocalized with soft drusen were observed.
Reticular pseudodrusen represent as small hyperreflectiv-
ities in OCT directly on top of the RPE. Depending on the
FIGURE 1. Autofluorescence lifetime imaging (FLIO) in the left eye of a patient with reticular pseudodrusen and soft retinal drusen due to age-
related macular degeneration (A) and a healthy control eye (B). Multimodal imaging with corresponding CF, IR, FAF, and autofluorescence lifetime
images (FLIO, short and long spectral channel [SSC¼498 to 560 nm, LSC¼560 to 720 nm]) is shown. (B) Healthy control eye with indicated way of
data analysis. A standard ETDRS grid (center [diameter; d ¼ 1 mm], inner [d ¼ 3 mm] and the outer [d ¼ 6 mm] ETDRS ring) was used for data
averaging. The indicated sample size circle (d ¼ 0.2 mm) was used for analysis of specific regions (ROI). (C) Comparison of mean fluorescence
lifetimes from the outer ETDRS ring in AMD and healthy control eyes.
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morphology and integrity of the overlying boundary between
the inner segments (ISs) and the outer segments (OSs) of the
photoreceptors (IS/OS boundary), reticular pseudodrusen can
be classified in four stages.31 In autofluorescence intensity
measurements, reticular pseudodrusen appear as small foci of
hypo-autofluorescence surrounded by dispersed hyper-auto-
fluorescence in a reticular pattern. Hypo-fluorescence is likely
to result from blockage of RPE fluorescence by overlying
reticular pseudodrusen. Despite their subretinal localization,
the autofluorescence pattern suggests that these drusen do not
contain high contents of bisretinoids.4 The relative lack of
autofluorescence and the small size of these deposits, which
are possibly below the resolution of the FLIO device, did not
allow identifying individual reticular pseudodrusen with FLIO.
FIGURE 2. FLIO in soft drusen (A) and reticular pseudodrusen (B). (C)
Quantitative analysis of fluorescence lifetimes in the long spectral
channel for control eyes and soft drusen respectively reticular
pseudodrusen in AMD. FAF, autofluorescence lifetime images (FLIO,
long spectral channel LSC ¼ 560 to 720 nm), CF, and OCT of the
indicated green line in the FAF image.
FIGURE 3. Correlation of fluorescence lifetime findings with OCT. (A)
Areas of short fluorescence lifetimes (red) in FLIO corresponded to
hyperfluorescent areas in FAF images and to hyperdense deposits in the
photoreceptor outer segment–RPE band in the OCT images. (B) Areas
of long fluorescence lifetimes (blue) in FLIO corresponded to
intraretinal hyperreflective deposits overlying a large druse. Soft
drusen as seen in OCT did not contrast with the surrounding retina
in FLIO. FAF intensity, autofluorescence lifetime images (FLIO, long
spectral channel LSC¼ 560 to 720 nm; color scale, 300 to 700 ps), and
OCT of the indicated green line in the FAF image.
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Areas of short fluorescence lifetimes in FLIO correlated
with hyperdense deposits in the photoreceptor outer segment
band and subretinal deposits in our study. Photoreceptor-
derived subclinical subretinal deposits after atrophy of the
photoreceptors were already proposed by Sarks et al. in
1988.32 The finding of short retinal fluorescence lifetimes in
areas of accumulated or thickened photoreceptor segments is
in accordance with our previous studies.14,17 In Stargardt
disease, we identified flecks with very short fluorescence
lifetimes and speculated that these represent bisretinoids
deriving from the visual cycle. Likewise, areas with elongated
outer photoreceptor segments in patients with central serous
chorioretinopathy had a marked reduction of fluorescence
lifetimes. These shed outer segments containing retinoids such
as retinaldehyde adducts and highly polyunsaturated fatty
acids.33 Considering these findings, we speculate that short
fluorescence lifetimes found in a subgroup of drusen are an
indicator for newly developing drusen with dysfunctional
outer segment phagocytosis. Further studies are warranted to
confirm this hypothesis.
Long retinal autofluorescence lifetimes can result from
retinal atrophy as seen in the area of geographic atrophy.16
However, long lifetimes were also seen in areas with preserved
retinal layer structure. These long lifetime spots corresponded
to intraretinal hyperdensities in OCT, which are described as
aberrant or migrated dysfunctional RPE cells or cell frag-
ments.34 The migration of RPE cells is assumed to be facilitated
by the prevalence of underlying drusen. To identify the
potential of FLIO as a diagnostic tool to record disease
development over time and to find early markers to identify
patients with progression from an early stage to intermediate
or late stages of AMD, follow-up examinations will be crucial.
This could provide a baseline for early intervention and drug
development to prevent or delay progressive irreversible loss
of retinal structure and function.
CONCLUSIONS
Retinal autofluorescence lifetimes in AMD were significantly
prolonged compared with healthy control eyes. Drusen exhibit
variable fluorescence lifetime characteristics not only associat-
ed with respective location and concurrent RPE changes. As
such, fluorescence lifetime features may change within
individual drusen over time and may help to identify newly
formed drusen. Longitudinal studies are currently underway to
investigate the significance of drusen lifetimes as biomarker for
disease progression.
Acknowledgments
The authors thank Joerg Fischer, PhD, Yoshihiko Katayama, PhD,
and Kester Nahen, PhD (Heidelberg Engineering GmBH, Heidel-
berg, Germany), for providing technical assistance for the FLIO
device.
Supported by Swiss National Science Foundation Grant
320030_156019 (Bern, Switzerland). The sponsor or funding
organization had no role in the design or conduct of this research.
Disclosure: C. Dysli, Heidelberg Engineering (S); R. Fink, None;
S. Wolf, Heidelberg Engineering (C, S), Bayer (C), Novartis, (C),
Alcon (C), Allergan (C), Roche (C); M.S. Zinkernagel, Heidelberg
Engineering (S), Bayer (C), Novartis (C, I)
References
1. Wilde C, Poostchi A, Mehta RL, et al. Prevalence of age-related
macular degeneration in an elderly UK Caucasian popula-
tion—The Bridlington Eye Assessment Project: a cross-
sectional study. Eye (Lond). 2017;31:1042–1050.
2. Lambert NG, ElShelmani H, Singh MK, et al. Risk factors and
biomarkers of age-related macular degeneration. Prog Retinal
Eye Res. 2016;54:64–102.
3. Korner-Stiefbold U. Age-related macular degeneration (AMD):
therapeutic possibilities and new approaches [in German].
Ther Umsch. 2001;58:28–35.
4. Khan KN, Mahroo OA, Khan RS, et al. Differentiating drusen:
drusen and drusen-like appearances associated with ageing,
age-related macular degeneration, inherited eye disease and
other pathological processes. Prog Retinal Eye Res. 2016;53:
70–106.
5. Tomany SC, Wang JJ, Van Leeuwen R, et al. Risk factors for
incident age-related macular degeneration: pooled findings
from 3 continents. Ophthalmology. 2004;111:1280–1287.
6. Zinkernagel MS, Zysset-Burri DC, Keller I, et al. Association of
the intestinal microbiome with the development of neovas-
cular age-related macular degeneration. Sci Rep. 2017;7:
40826.
7. Reim M, Kirchhof B, Wolf S. Diagnose am Augenhintergrund
[in German]. Stuttgart, Germany: Georg Thieme Verlag; 2004.
8. Spaide RF, Curcio CA. Drusen characterization with multi-
modal imaging. Retina. 2010;30:1441–1454.
9. Schutt F, Ueberle B, Schnolzer M, Holz FG, Kopitz J. Proteome
analysis of lipofuscin in human retinal pigment epithelial
cells. FEBS Lett. 2002;528:217–221.
10. Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, Curcio
CA. Sub-retinal drusenoid deposits in human retina: organi-
zation and composition. Exp Eye Res. 2008;87:402–408.
FIGURE 4. Lifetime distribution histogram in deposits of short and long
fluorescence lifetimes. (A) FAF intensity, autofluorescence lifetime
images (FLIO, long spectral channel LSC ¼ 560 to 720 nm; color scale,
300 to 700 ps), and OCT of the indicated red and blue lines in the FAF
image are shown below. (B) Lifetime clouds of short and long mean
fluorescence lifetimes were clearly identifiable using the 2D histograms
(T1 against T2; see Equation 1). Corresponding areas are highlighted in
B1–3 below.
Fluorescence lifetime imaging in retinal drusen IOVS j September 2017 j Vol. 58 j No. 11 j 4861
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936468/ on 12/13/2017
11. Ferris FL III, Wilkinson CP, Bird A, et al. Clinical classification
of age-related macular degeneration. Ophthalmology. 2013;
120:844–851.
12. Klein R, Myers CE, Lee KE, et al. Small drusen and age-related
macular degeneration: the Beaver Dam Eye Study. J Clin Med.
2015;4:424–440.
13. Dysli C, Quellec G, Abegg M, et al. Quantitative analysis of
fluorescence lifetime measurements of the macula using the
fluorescence lifetime imaging ophthalmoscope in healthy
subjects. Invest Ophthalmol Vis Sci. 2014;55:2106–2113.
14. Dysli C, Wolf S, Hatz K, Zinkernagel MS. Fluorescence lifetime
imaging in stargardt disease: potential marker for disease
progression. Invest Ophthalmol Vis Sci. 2016;57:832–841.
15. Dysli C, Wolf S, Zinkernagel MS. Fluorescence lifetime
imaging in retinal artery occlusion. Invest Ophthalmol Vis
Sci. 2015;56:3329–3336.
16. Dysli C, Wolf S, Zinkernagel MS. Autofluorescence lifetimes in
geographic atrophy in patients with age-related macular
degeneration. Invest Ophthalmol Vis Sci. 2016;57:2479–
2487.
17. Dysli C, Berger L, Wolf S, Zinkernagel MS. Fundus autofluo-
rescence lifetimes and central serous chorioretinopathy
[published online ahead of print January 17, 2017]. Retina.
doi:10.1097/IAE.0000000000001452.
18. Dysli C, Wolf S, Tran HV, Zinkernagel MS. Autofluorescence
lifetimes in patients with choroideremia identify photorecep-
tors in areas with retinal pigment epithelium atrophy. Invest
Ophthalmol Vis Sci. 2016;57:6714–6721.
19. Sauer L, Schweitzer D, Ramm L, Augsten R, Hammer M, Peters
S. Impact of macular pigment on fundus autofluorescence
lifetimes. Invest Ophthalmol Vis Sci. 2015;56:4668–4679.
20. Sauer L, Peters S, Schmidt J, et al. Monitoring macular pigment
changes in macular holes using fluorescence lifetime imaging
ophthalmoscopy. Acta Ophthalmol. 2017;95:481–492.
21. Schmidt J, Peters S, Sauer L, et al. Fundus autofluorescence
lifetimes are increased in non-proliferative diabetic retinopa-
thy. Acta Ophthalmol. 2017;95:33–40.
22. Dysli C, Wolf S, Berezin MY, Sauer L, Hammer M, Zinkernagel
MS. Fluorescence lifetime imaging ophthalmoscopy [pub-
lished online ahead of print June 30, 2017]. Prog Retinal Eye
Res. doi:10.1016/j.preteyeres.2017.06.005.
23. Schweitzer D, Schenke S, Hammer M, et al. Towards
metabolic mapping of the human retina. Microscopy Res
Technique. 2007;70:410–419.
24. Schweitzer D, Quick S, Schenke S, et al. Comparison of
parameters of time-resolved autofluorescence between
healthy subjects and patients suffering from early AMD [in
German]. Der Ophthalmologe: Zeitschrift der Deutschen
Ophthalmologischen Gesellschaft. 2009;106:714–722.
25. Schweitzer D, Hammer M, Schweitzer F, et al. In vivo
measurement of time-resolved autofluorescence at the human
fundus. J Biomed Optics. 2004;9:1214–1222.
26. Early Treatment Diabetic Retinopathy Study Research Group.
Early Treatment Diabetic Retinopathy Study design and
baseline patient characteristics. ETDRS report number 7.
Ophthalmology. 1991;98(5 Suppl):741–756.
27. International Electrotechnical Commission. Safety of laser
products - part 1: equipment classification and requirements.
In: IEC 60825-1:2014. 3rd ed. International Electrotechnical
Commission; 2014.
28. Schweitzer D, Gaillard ER, Dillon J, et al. Time-resolved
autofluorescence imaging of human donor retina tissue from
donors with significant extramacular drusen. Invest Ophthal-
mol Vis Sci. 2012;53:3376–3386.
29. Schweitzer D. Metabolic mapping. In: Holz FG, Spaide RF, eds.
Medical Retina: Essentials in Ophthalmology. Berlin: Spring-
er-Verlag; 2010:107–123.
30. Solbach U, Keilhauer C, Knabben H, Wolf S. Imaging of retinal
autofluorescence in patients with age-related macular degen-
eration. Retina. 1997;17:385–389.
31. Zweifel SA, Spaide RF, Curcio CA, Malek G, Imamura Y.
Reticular pseudodrusen are subretinal drusenoid deposits.
Ophthalmology. 2010;117:303–312.
32. Sarks JP, Sarks SH, Killingsworth MC. Evolution of geographic
atrophy of the retinal pigment epithelium. Eye (Lond). 1988;
2(Pt 5):552–577.
33. Warburton S, Southwick K, Hardman R, et al. Examining the
proteins of functional retinal lipofuscin using proteomic
analysis as a guide for understanding its origin. Molec Vis.
2005:1122–1134.
34. Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal
retinal pigment epithelium migration via high-speed ultra-
high-resolution optical coherence tomography. Ophthalmol-
ogy. 2011;118:687–693.
Fluorescence lifetime imaging in retinal drusen IOVS j September 2017 j Vol. 58 j No. 11 j 4862
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/936468/ on 12/13/2017
